tretinoin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
retinol derivatives	2722	302-79-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tretinoin potassium trans-Retinoic acid tretinoin sodium retinoic acid tretinoin	An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE). Molecular weight: 300.44 Formula: C20H28O2 CLOGP: 6.74 LIPINSKI: 1 HAC: 2 HDO: 1 TPSA: 37.30 ALOGS: -4.80 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tretinoin potassium
trans-Retinoic acid
tretinoin sodium
retinoic acid
tretinoin

An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).

Molecular weight: 300.44
Formula: C20H28O2
CLOGP: 6.74
LIPINSKI: 1
HAC: 2
HDO: 1
TPSA: 37.30
ALOGS: -4.80
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.70 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Oct. 20, 1971	FDA	VALEANT INTL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Differentiation syndrome	600.18	16.69	104	6423	829	50597768
Idiopathic intracranial hypertension	117.50	16.69	32	6495	2317	50596280
Blepharospasm	110.30	16.69	32	6495	2916	50595681
Product use in unapproved indication	109.47	16.69	102	6425	115717	50482880
Intracranial pressure increased	86.68	16.69	29	6498	4223	50594374
Leukaemia recurrent	76.54	16.69	20	6507	1234	50597363
Taste disorder	74.39	16.69	31	6496	8293	50590304
Epilepsy	49.01	16.69	32	6495	21535	50577062
Haematopoietic neoplasm	42.99	16.69	7	6520	36	50598561
Polyarteritis nodosa	35.68	16.69	8	6519	257	50598340
Lower respiratory tract infection fungal	34.83	16.69	8	6519	287	50598310
Migraine	33.82	16.69	45	6482	75235	50523362
Dysphoria	33.53	16.69	15	6512	4759	50593838
Dry skin	33.13	16.69	34	6493	43157	50555440
Hypoaesthesia	33.04	16.69	59	6468	127198	50471399
Haemorrhagic diathesis	32.92	16.69	14	6513	3934	50594663
Skin warm	30.48	16.69	14	6513	4721	50593876
Chromosomal deletion	29.65	16.69	5	6522	33	50598564
Disseminated intravascular coagulation	28.52	16.69	21	6506	17114	50581483
Myelodysplastic syndrome	28.52	16.69	20	6507	15112	50583485
Gastrooesophageal reflux disease	27.37	16.69	41	6486	76387	50522210
Appetite disorder	27.07	16.69	14	6513	6100	50592497
Chloroma	26.41	16.69	6	6521	205	50598392
Arthritis infective	25.38	16.69	13	6514	5556	50593041
Neutropenic sepsis	25.05	16.69	18	6509	14129	50584468
Xerosis	24.20	16.69	7	6520	630	50597967
Acute myeloid leukaemia	24.02	16.69	18	6509	15056	50583541
Myocarditis	23.64	16.69	14	6513	7933	50590664
Memory impairment	23.47	16.69	39	6488	79321	50519276
Febrile neutropenia	22.46	16.69	43	6484	97624	50500973
Oesophageal mass	21.28	16.69	4	6523	52	50598545
Thinking abnormal	21.25	16.69	14	6513	9553	50589044
Tenderness	20.72	16.69	18	6509	18547	50580050
Gambling	20.54	16.69	5	6522	231	50598366
Paraesthesia	19.59	16.69	46	6481	120197	50478400
Neutropenia	19.29	16.69	52	6475	147913	50450684
Sweat gland tumour	18.66	16.69	4	6523	104	50598493
VIth nerve paralysis	18.54	16.69	6	6521	787	50597810
Lip dry	18.47	16.69	10	6517	4777	50593820
Papilloedema	18.46	16.69	9	6518	3464	50595133
Photophobia	17.77	16.69	15	6512	14872	50583725
Erythema	17.64	16.69	50	6477	146364	50452233
Hypercalcaemia	17.21	16.69	18	6509	23334	50575263
Chloasma	16.87	16.69	3	6524	28	50598569
Application site dryness	16.85	16.69	4	6523	166	50598431

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Differentiation syndrome	751.97	26.39	121	2307	992	29571107
Idiopathic intracranial hypertension	195.41	26.39	35	2393	560	29571539
Product use in unapproved indication	84.24	26.39	64	2364	86811	29485288
Haematopoietic neoplasm	82.44	26.39	12	2416	44	29572055
Acute myeloid leukaemia	80.38	26.39	35	2393	16478	29555621
Hyperleukocytosis	80.29	26.39	20	2408	1615	29570484
Leukaemia recurrent	72.19	26.39	18	2410	1459	29570640
Electrocardiogram QT prolonged	69.94	26.39	41	2387	36096	29536003
Cytogenetic abnormality	55.54	26.39	13	2415	806	29571293
Scrotal ulcer	48.26	26.39	10	2418	351	29571748
Hypokalaemia	44.19	26.39	35	2393	50168	29521931
Febrile neutropenia	39.09	26.39	47	2381	112193	29459906
Myelodysplastic syndrome	36.52	26.39	21	2407	17773	29554326
IIIrd nerve paralysis	35.02	26.39	8	2420	445	29571654
Neutropenia	34.64	26.39	48	2380	131663	29440436
Hypomagnesaemia	31.59	26.39	19	2409	17449	29554650
Lymphopenia	30.54	26.39	17	2411	13516	29558583
Large granular lymphocytosis	29.49	26.39	6	2422	192	29571907
Activated partial thromboplastin time prolonged	26.90	26.39	13	2415	7729	29564370

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Differentiation syndrome	1284.49	17.59	221	7534	1833	64489144
Idiopathic intracranial hypertension	240.41	17.59	57	7698	2536	64488441
Myelodysplastic syndrome transformation	160.18	17.59	32	7723	627	64490350
Product use in unapproved indication	129.38	17.59	131	7624	176487	64314490
Leukaemia recurrent	107.36	17.59	30	7725	2564	64488413
Blepharospasm	99.56	17.59	30	7725	3345	64487632
Hyperleukocytosis	90.89	17.59	25	7730	2015	64488962
Acute myeloid leukaemia	81.24	17.59	47	7708	27416	64463561
Haematopoietic neoplasm	71.63	17.59	12	7743	82	64490895
Intracranial pressure increased	67.57	17.59	27	7728	6962	64484015
Cytogenetic abnormality	66.43	17.59	17	7738	1037	64489940
Taste disorder	66.19	17.59	29	7726	9404	64481573
Myelodysplastic syndrome	58.07	17.59	38	7717	27541	64463436
Electrocardiogram QT prolonged	49.22	17.59	54	7701	79394	64411583
Second primary malignancy	47.13	17.59	25	7730	12312	64478665
Febrile neutropenia	46.61	17.59	82	7673	187575	64303402
Hypercalcaemia	42.36	17.59	33	7722	31383	64459594
Myocarditis	37.14	17.59	24	7731	17019	64473958
Neutropenia	35.98	17.59	85	7670	239539	64251438
Disseminated intravascular coagulation	35.22	17.59	30	7725	32318	64458659
Migraine	34.37	17.59	40	7715	62637	64428340
Dysphoria	32.44	17.59	14	7741	4374	64486603
Epilepsy	32.29	17.59	29	7726	33502	64457475
Polyarteritis nodosa	31.63	17.59	8	7747	465	64490512
Gastrointestinal toxicity	29.85	17.59	14	7741	5308	64485669
Hypoaesthesia	28.50	17.59	56	7699	139052	64351925
Chloroma	28.47	17.59	8	7747	697	64490280
Lower respiratory tract infection fungal	26.94	17.59	8	7747	847	64490130
Haemorrhagic diathesis	26.36	17.59	13	7742	5501	64485476
Chromosomal deletion	25.53	17.59	5	7750	88	64490889
IIIrd nerve paralysis	25.14	17.59	8	7747	1066	64489911
White blood cell count increased	24.92	17.59	35	7720	65979	64424998
Scrotal ulcer	24.55	17.59	6	7749	303	64490674
Appetite disorder	24.41	17.59	13	7742	6448	64484529
Large granular lymphocytosis	23.82	17.59	6	7749	343	64490634
Papilloedema	23.44	17.59	12	7743	5493	64485484
Acute promyelocytic leukaemia	23.13	17.59	8	7747	1380	64489597
Skin warm	23.01	17.59	12	7743	5705	64485272
Dry skin	22.15	17.59	29	7726	51132	64439845
Ciliary body melanoma	22	17.59	3	7752	3	64490974
Bone marrow necrosis	21.69	17.59	5	7750	196	64490781
Gastrooesophageal reflux disease	21.46	17.59	37	7718	83106	64407871
Tenderness	20.97	17.59	18	7737	19584	64471393
Acute myeloid leukaemia recurrent	20.96	17.59	9	7746	2775	64488202
Photophobia	20.81	17.59	17	7738	17276	64473701
Arthritis infective	20.69	17.59	12	7743	7018	64483959
Oesophageal mass	20.61	17.59	4	7751	67	64490910
Thinking abnormal	19.74	17.59	14	7741	11542	64479435
Acute febrile neutrophilic dermatosis	19.42	17.59	9	7746	3320	64487657
Memory impairment	19.39	17.59	36	7719	85646	64405331
Hypomagnesaemia	19.07	17.59	23	7732	37353	64453624
Paraesthesia	18.31	17.59	46	7709	134476	64356501
Pulmonary tuberculosis	17.77	17.59	11	7744	7233	64483744
Gelatinous transformation of the bone marrow	17.60	17.59	3	7752	23	64490954

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D10AD01	DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Retinoids for topical use in acne
ATC	D10AD51	DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Retinoids for topical use in acne
ATC	L01XF01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Retinoids for cancer treatment
FDA CS	M0018962	Retinoids
CHEBI has role	CHEBI:22586	antioxidants
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:50176	keratolytic drugs
CHEBI has role	CHEBI:62488	signal molecules
CHEBI has role	CHEBI:63794	retinoid X receptor agonists
CHEBI has role	CHEBI:67079	anti-inflammatory agents
CHEBI has role	CHEBI:67198	retinoic acid receptor agonists
CHEBI has role	CHEBI:67199	activator protein-1 antagonists
CHEBI has role	CHEBI:77746	Homo sapiens metabolite
FDA EPC	N0000175607	Retinoid
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D007641	Keratolytic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chloasma	indication	36209000
Acne vulgaris	indication	88616000
Acute promyelocytic leukemia, FAB M3	indication	110004001
Hyperkeratosis	indication	396228006
Facial Fine Wrinkling	indication
Solar Lentigines	indication
Fine Wrinkling	indication
Severe Recalcitrant Nodular Acne	indication
Kaposi's Sarcoma Skin Lesions	indication
Mottle Hyperpigmentation	indication
Keratosis follicularis	off-label use	48611009	DOID:2734
Lamellar ichthyosis	off-label use	205550003
Plane wart	off-label use	240539000
Primary cutaneous T-cell lymphoma	off-label use	400122007
Severe Recalcitrant Nodular Rosacea	off-label use
Osteomalacia	contraindication	4598005	DOID:10573
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Rectal hemorrhage	contraindication	12063002
Hypercholesterolemia	contraindication	13644009
Hearing loss	contraindication	15188001
Agranulocytosis	contraindication	17182001	DOID:12987
Myocardial infarction	contraindication	22298006	DOID:5844
Sunburn	contraindication	23346002
Atopic dermatitis	contraindication	24079001	DOID:3310
Inflammatory bowel disease	contraindication	24526004	DOID:0050589
Crohn's disease	contraindication	34000006
Depressive disorder	contraindication	35489007
Eczema	contraindication	43116000
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Vitiligo	contraindication	56727007	DOID:12306
Anorexia nervosa	contraindication	56882008	DOID:8689
Tinnitus	contraindication	60862001
Corneal opacity	contraindication	64634000
Ulcerative colitis	contraindication	64766004	DOID:8577
Osteoporosis	contraindication	64859006	DOID:11476
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Psychotic disorder	contraindication	69322001
Diabetes mellitus	contraindication	73211009	DOID:9351
Disorder of bone	contraindication	76069003	DOID:0080001
Congenital neutropenia	contraindication	89655007
Kidney disease	contraindication	90708001	DOID:557
Venous thrombosis	contraindication	111293003
Leukocytosis	contraindication	111583006
Mycosis fungoides	contraindication	118618005
Inflammatory disease of liver	contraindication	128241005
Bleeding	contraindication	131148009
Liver function tests abnormal	contraindication	166603001
Acute pancreatitis	contraindication	197456007	DOID:2913
Disease of liver	contraindication	235856003	DOID:409
Telangiectasia disorder	contraindication	247479008
Dyspnea	contraindication	267036007
Edema	contraindication	267038008
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Keratoconjunctivitis sicca	contraindication	302896008	DOID:12895
Neutropenic disorder	contraindication	303011007	DOID:1227
Pericardial effusion	contraindication	373945007	DOID:118
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Fever	contraindication	386661006
Pseudomembranous enterocolitis	contraindication	397683000
Atrophoderma	contraindication	399979006
Peripheral vascular disease	contraindication	400047006
Severe diarrhea	contraindication	409587002
Breastfeeding (mother)	contraindication	413712001
Obesity	contraindication	414916001	DOID:9970
Denuded skin	contraindication	418242004
Retinoic acid syndrome	contraindication	450887006
Pulmonary Infiltrates	contraindication
Pleural Effusions	contraindication
Predisposition To Hypertriglyceridemia	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.17	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
3%;0.1%	TWYNEO	GALDERMA LABS LP	N214902	July 26, 2021	RX	CREAM	TOPICAL	9868103	Aug. 8, 2028	TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
3%;0.1%	TWYNEO	GALDERMA LABS LP	N214902	July 26, 2021	RX	CREAM	TOPICAL	10653899	Dec. 30, 2030	TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
3%;0.1%	TWYNEO	GALDERMA LABS LP	N214902	July 26, 2021	RX	CREAM	TOPICAL	10420743	July 12, 2038	TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
0.05%	ALTRENO	DOW PHARM	N209353	Aug. 23, 2018	RX	LOTION	TOPICAL	10653656	Aug. 22, 2038	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER
0.05%	ALTRENO	DOW PHARM	N209353	Aug. 23, 2018	RX	LOTION	TOPICAL	11324710	Aug. 22, 2038	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1.2%;0.025%	CLINDAMYCIN PHOSPHATE AND TRETINOIN	SOLARIS PHARMA CORP	A212845	Feb. 10, 2022	RX	GEL	TOPICAL	Oct. 9, 2022	COMPETITIVE GENERIC THERAPY
3%;0.1%	TWYNEO	GALDERMA LABS LP	N214902	July 26, 2021	RX	CREAM	TOPICAL	July 26, 2024	NEW COMBINATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Retinoic acid receptor beta	Nuclear hormone receptor	P10826	RARB_HUMAN	AGONIST	EC50	6.70	WOMBAT-PK	CHEMBL
Retinoic acid receptor gamma	Nuclear hormone receptor	P13631	RARG_HUMAN	AGONIST	EC50	6.70	WOMBAT-PK	CHEMBL
Retinoic acid receptor alpha	Nuclear hormone receptor	P10276	RARA_HUMAN	AGONIST	EC50	6.70	WOMBAT-PK	CHEMBL
Nuclear receptor ROR-alpha	Nuclear hormone receptor	P35398	RORA_HUMAN		IC50	6.70	CHEMBL
Retinoic acid receptor RXR-alpha	Nuclear hormone receptor	P19793	RXRA_HUMAN		Ki	9.40	CHEMBL
Retinoic acid receptor RXR-beta	Nuclear hormone receptor	P28702	RXRB_HUMAN		Ki	9.30	CHEMBL
Retinoic acid receptor RXR-gamma	Nuclear hormone receptor	P48443	RXRG_HUMAN		Ki	8.85	CHEMBL
Peroxisome proliferator-activated receptor delta	Nuclear hormone receptor	Q03181	PPARD_HUMAN	AGONIST	Kd	7.80	IUPHAR
Nuclear receptor ROR-beta	Nuclear hormone receptor	Q92753	RORB_HUMAN	ANTAGONIST	IC50	9.82	IUPHAR
Nuclear receptor ROR-gamma	Nuclear hormone receptor	P51449	RORG_HUMAN		IC50	6.70	CHEMBL
Mitogen-activated protein kinase 1	Kinase	P28482	MK01_HUMAN		IC50	6.24	DRUG MATRIX
Nuclear receptor subfamily 2 group E member 1	Nuclear hormone receptor	Q9Y466	NR2E1_HUMAN	AGONIST	EC50	5.74	IUPHAR
Amyloid beta A4 protein	Unclassified	P05067	A4_HUMAN		IC50	6.75	CHEMBL
Nuclear receptor subfamily 2 group C member 2	Nuclear other	P49116	NR2C2_HUMAN	AGONIST	EC50	4.62	IUPHAR
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Unclassified	Q13526	PIN1_HUMAN		IC50	6.09	CHEMBL
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.64	DRUG MATRIX
Alpha-synuclein	Transporter	P37840	SYUA_HUMAN		IC50	5.52	CHEMBL
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.53	DRUG MATRIX
11-cis retinol dehydrogenase	Enzyme	Q92781	RDH1_HUMAN		Ki	7	WOMBAT-PK
Cellular retinoic acid-binding protein 1	Cytosolic other		RABP1_CHICK		IC50	6.43	CHEMBL
Retinoic acid receptor RXR-beta	Transcription factor		RXRB_MOUSE		Kd	6.51	CHEMBL
Retinoic acid receptor RXR-gamma	Transcription factor		RXRG_MOUSE		Kd	6.46	CHEMBL
Cellular retinoic acid-binding protein 1	Cytosolic other		RABP1_MOUSE		Kd	9.40	CHEMBL
Cellular retinoic acid-binding protein 2	Cytosolic other		RABP2_MOUSE		Kd	8.70	CHEMBL
Retinoic acid receptor alpha	Transcription factor		RARA_MOUSE		Kd	7.82	CHEMBL
Retinoic acid receptor RXR-alpha	Transcription factor		RXRA_MOUSE		Kd	6	CHEMBL
Retinoic acid receptor beta	Transcription factor		RARB_MOUSE		Kd	7.89	CHEMBL
Retinoic acid receptor gamma	Transcription factor		RARG_MOUSE		Kd	7.74	CHEMBL
Indoleamine 2,3-dioxygenase 2	Enzyme		I23O2_MOUSE		IC50	4.54	CHEMBL

External reference:

ID	Source
4018550	VUID
N0000146871	NUI
D00094	KEGG_DRUG
4018550	VANDF
C0040845	UMLSCUI
CHEBI:15367	CHEBI
3KV	PDB_CHEM_ID
CHEMBL38	ChEMBL_ID
DB00755	DRUGBANK_ID
D014212	MESH_DESCRIPTOR_UI
444795	PUBCHEM_CID
2644	IUPHAR_LIGAND_ID
2875	INN_ID
5688UTC01R	UNII
10753	RXNORM
46802	MMSL
5610	MMSL
d03863	MMSL
001954	NDDF
387305002	SNOMEDCT_US
54972005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Altreno	HUMAN PRESCRIPTION DRUG LABEL	1	0187-0005	LOTION	0.50 mg	TOPICAL	NDA	24 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5140	GEL	1 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5140	GEL	1 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5144	GEL	0.40 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5144	GEL	0.40 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5146	GEL	0.60 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5146	GEL	0.60 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5148	GEL	0.80 mg	TOPICAL	NDA	26 sections
Retin-A MICRO	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5148	GEL	0.80 mg	TOPICAL	NDA	26 sections
Renova	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5150	CREAM	0.20 mg	TOPICAL	NDA	25 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5160	CREAM	0.25 mg	TOPICAL	NDA	21 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5162	CREAM	0.50 mg	TOPICAL	NDA	21 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5164	CREAM	1 mg	TOPICAL	NDA	21 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5170	GEL	0.25 mg	TOPICAL	NDA	21 sections
Retin-A	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5172	GEL	0.10 mg	TOPICAL	NDA	21 sections
TWYNEO	HUMAN PRESCRIPTION DRUG LABEL	2	0299-5945	CREAM	1 mg	TOPICAL	NDA	26 sections
TRI-LUMA	HUMAN PRESCRIPTION DRUG LABEL	3	0299-5950	CREAM	0.50 mg	TOPICAL	NDA	24 sections
TRI-LUMA	HUMAN PRESCRIPTION DRUG LABEL	3	0299-5950	CREAM	0.50 mg	TOPICAL	NDA	24 sections
Avita	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6140	GEL	0.25 mg	TOPICAL	NDA	22 sections
Avita	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6141	CREAM	0.25 mg	TOPICAL	NDA	21 sections
Tretinoin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8082	CREAM	0.25 mg	TOPICAL	NDA authorized generic	20 sections
Tretinoin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8083	CREAM	0.50 mg	TOPICAL	NDA authorized generic	20 sections
Tretinoin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8084	CREAM	1 mg	TOPICAL	NDA authorized generic	20 sections
Tretinoin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8085	GEL	0.10 mg	TOPICAL	NDA authorized generic	20 sections
Tretinoin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8086	GEL	0.25 mg	TOPICAL	NDA authorized generic	20 sections
Tretinoin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8090	GEL	0.50 mg	TOPICAL	ANDA	24 sections
Tretinoin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8092	GEL	0.40 mg	TOPICAL	NDA authorized generic	25 sections
Tretinoin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8093	GEL	1 mg	TOPICAL	NDA authorized generic	25 sections
Tretinoin	HUMAN PRESCRIPTION DRUG LABEL	1	0472-0117	CREAM	0.25 mg	TOPICAL	NDA AUTHORIZED GENERIC	22 sections
Clindamycin Phosphate and Tretinoin	HUMAN PRESCRIPTION DRUG LABEL	2	0472-1790	GEL	0.25 mg	TOPICAL	ANDA	16 sections